GENE ONLINE|News &
Opinion
Blog

Deals
BMS Returns $475 Million Cancer Asset To Dragonfly Therapeutics
2023-02-07
Karuna Licenses Goldfinch’s Mood Disorder Candidates For Potential $535 Million
2023-02-03
Sherlock Biosciences Buys Sense Biodetection to Accelerate CRISPR-Based Handheld Diagnostic Tests
2023-02-02
CARsgen Taps Huadong to Commercialize Multiple Myeloma CAR-T in China
2023-01-17
Bayer Signs Up To Google Cloud To Boost Drug Discovery
2023-01-13
In-Home Kidney Disease Management Company, Monogram, Raises $375 Million
2023-01-13
JPM23: More Deals as JP Morgan Healthcare Conference 2023 Enters the Third Day
2023-01-12
JPM23: More Deals Defining JP Morgan Healthcare Conference 2023 Day Two
2023-01-11
JPM23: Development and Strategic Updates from JP Morgan Healthcare Conference 2023 Day Two
2023-01-10
JPM23: Partnerships Take off From JP Morgan Healthcare Conference 2023 Day One
2023-01-10
JPM23: Acquisition Announcements From JP Morgan Healthcare Conference 2023 Day One
2023-01-10
Italy’s Chiesi Buys Rare Disease Player Amryt For $1.48 Billion
2023-01-09
Following Amgen, Hummingbird Jumps Onto Synaffix’s ADC Platform In $150 Million Licensing Deal
2023-01-06
Soon-To-Be J&J Spinoff, Kenvue Files for $100 Million IPO
2023-01-06
Belharra Therapeutics Exits Stealth With $130 Million And A Genentech Deal
2023-01-05
1 2 3 38
LATEST
NDA for Biogen-Sage’s Zuranolone Accepted by FDA, Marking Another Step Forward in Depression Drug Development
2023-02-07
FDA Expands Approval For Takeda’s Takhzyro To Prevent Hereditary Angioedema Attacks
2023-02-06
Abbott’s New Technologies for Arrhythmia Treatment Secure FDA and European Approval
2023-02-04
First Human Trial for Marburg Virus Vaccine Reports Success
2023-02-03
Karuna Licenses Goldfinch’s Mood Disorder Candidates For Potential $535 Million
2023-02-03
Novel Bioengineered Wearable Edgeless Skin Brings Hope to Revolutionize Plastic and Reconstructive Surgery
2023-02-03
Scientists Use iPSCs to Grow Mature Neurons to Study Neurodegenerative Diseases
2023-02-02
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!